Search the Newsreel

ETFs Investing in Clarivate PLC Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Clarivate PLC (16A) stocks, providing investors with options to invest in the company indirectly. Each ETF entry includes details such as market value, weight of Clarivate PLC in the fund, issuer, management style, focus, …

Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS

Dimensional Fund Advisors LP significantly increased its stake in Aclaris Therapeutics, Inc. by 88.8% in the first quarter, now holding 511,461 shares valued at approximately $1.91 million. This move is part of a broader trend of institutional investment, with such entities owning 98.34% of …

Claritev (CTEV) Stock Fair Value Rises After Analysts Weigh Growth Against Leverage Risks

Does Clarivate’s Expanded Agentic AI Across Cortellis Reshape the Bull Case For Clarivate (CLVT)?

Clarivate Plc has expanded agentic AI capabilities across its Cortellis life sciences portfolio, aiming to integrate AI into drug discovery, safety assessment, and portfolio decision workflows. This move seeks to reduce manual effort and support faster, evidence-based decisions, reinforcing Clarivate's investment narrative around workflow …

Is Clarivate (CLVT) Below Fair Value On Its Cortellis Agentic AI Expansion?

Clarivate (CLVT) has expanded its Cortellis portfolio with new agentic AI capabilities aimed at accelerating life sciences R&D, despite its stock experiencing a significant decline. The company's valuation narrative suggests it is undervalued at $2.50 per share compared to its current price of $1.91, …

Clarivate : and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes

Clarivate and KYBORA have partnered to offer integrated, end-to-end transaction advisory services for bioph

HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings

Clarivate (NYSE:CLVT) Shares Gap Up on Insider Buying Activity

Clarivate (NYSE:CLVT) shares gapped up after Director Kenneth L. Cornick purchased 900,000 shares across two transactions totaling approximately $1.67 million. This insider buying activity occurred despite cautious analyst sentiment, with a consensus "Reduce" rating and a price target of $3.02. The company slightly exceeded …

Clarivate PLC (16A.MU) Analyst Insights, Price Targets & Recommendations

This article provides analyst ratings and price targets for Clarivate PLC (16A.MU). It lists recent "Upgrades & Downgrades" showing various firms maintaining their ratings, including Citigroup, Goldman Sachs, Stifel, and Barclays, with the latest update on July 30, 2026. The stock's current price is …

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received an average "Buy" rating from brokerages, with an average 12-month price target of $11.50. Institutional investors hold a significant portion of the stock, and several firms increased their positions recently. The company also surpassed its latest quarterly earnings …

Kenneth Cornick Acquires 650,000 Shares of Clarivate (NYSE:CLVT) Stock

Clarivate director Kenneth Cornick recently acquired 650,000 shares of NYSE:CLVT stock for approximately $1.21 million, significantly increasing his direct ownership by 59.09% to 1.75 million shares. Despite Clarivate's shares rising 4.4% to $1.90, they remain near their one-year low, and analysts maintain a cautious …

Clarivate (NYSE:CLVT) Director Kenneth Cornick Buys 250,000 Shares of Stock

Clarivate (NYSE:CLVT) Director Kenneth Cornick purchased 250,000 shares of the company's stock on August 7th, investing $462,500 at an average price of $1.85 per share. This transaction increased his direct ownership to 2 million shares, a 14.29% increase. Despite the insider buying, analyst sentiment …

Claritev Analysts Raise Their Forecasts Following Q2 Earnings

Clarity Pharmaceuticals (ASX:CU6) Rises As SECuRE Trial Delivers More Responses

Canaccord raises Claritev stock price target to $43 on bookings

Enterprise value to EBIT forward of Clarivate Plc – NYSE:CLVT

The article focuses on the enterprise value to EBIT forward for Clarivate Plc (NYSE: CLVT). It presents financial data within the TradingView platform context, highlighting the company's stock information and financial metrics. The primary content available is a data point for this specific financial …

Claritev (CTEV) Stock Jumps On Margin Strength Despite Ongoing Losses

Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history

This page provides a comprehensive overview of Aclaris Therapeutics, Inc. (ACRS) stock, including its current price, historical data, key statistics, and company profile. Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immuno-inflammatory diseases, with several drug candidates in various trial …

Claritev Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:CTEV) 2026-08-08

Claritev Q2 Earnings Call Highlights

Key Points Interested in Claritev? Here are five stocks we like better. Strong second-quarter performance: Revenue rose 6.6% year over year to $257.5 million, while adjusted EBITDA reached $155.8 million and operating cash flow increased 51% to $93 million. Claims Intelligence, particularly No Surprises …

Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue

Aclaris Updates At-The-Market Equity Sales Agreement

Claritev signals $1.0B-$1.02B 2026 revenue outlook as bookings target stays at $100M

Earnings Call Insights: Claritev Corporation (CTEV) Q2 2026 MANAGEMENT VIEW * "We're pleased to announce another strong quarter for Claritev and continued progress on our turnaround journey." (CEO, President & Chairman Travis Dalton) "At our Investor Day in March, we introduced 2026 as the …

Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6% - Here's What Happened

Can Clarivate’s (CLVT) Agentic AI Push Deepen Its Moat Or Signal A Riskier Shift?

Clarivate Plc recently expanded agentic AI capabilities across its Cortellis portfolio, embedding natural language and multi‑agent tools into life sciences R&D, safety and competitive intelligence workflows to cut manual effort and speed evidence-based decisions. This move effectively turns Cortellis into a more embedded decision …

Claritev Stock (CTEV) Opinions on Q2 Earnings Beat

Claritev earnings beat by $0.67, revenue topped estimates

CTEV | Claritev Corporation Financials - Income Statement

Earnings call transcript: Claritev posts Q2 2026 beat, but shares fall premarket

Claritev (NYSE:CTEV) Trading 41.9% Higher After Strong Earnings

Claritev Corporation (CTEV) Reports Q2 Loss, Tops Revenue Estimates

Claritev Updates 2026 Revenue Guidance to $1B-$1.02B After Q2

Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates

Aclaris Therapeutics reported a widened net loss of $41.329 million for the first half of 2026, primarily due to increased research and development (R&D) spending on its immuno-inflammatory programs like bosakitug, ATI-052, modzatinib, and ATI-9494. Despite the losses, the company maintains $170.6 million in …